Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Kane Biotech Inc V.KNE

Alternate Symbol(s):  KNBIF

Kane Biotech Inc. is a Canada-based biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (68 patents and patents pending, trade secrets and trademarks) and products developed by its own biofilm research expertise and acquired from research institutions. DispersinB, Aledex, coactiv+, coactiv+, DermaKB, DermaKB Biofilm, and revyve are trademarks of the Company. Its patented coactiv+ technology is specifically formulated to destabilize biofilm and create an environment for fast wound healing. In Wound Care & Surgical applications, in addition to revyve Antimicrobial Wound Gel, it is developing follow-on products with three applications: coactiv+ Antimicrobial Surgical Hydrogel, coactiv+ Antimicrobial Wound Gel Spray, and coactiv+ Antimicrobial Wound Rinse. The Company's other biofilm disruption technology is DispersinB.


TSXV:KNE - Post by User

Bullboard Posts
Comment by NoPoliticsNoneon Jul 11, 2016 10:44pm
158 Views
Post# 25043173

RE:RE:News release - end of joint development with pharma firm

RE:RE:News release - end of joint development with pharma firmI don't think Burcon is a paid pumper. Rather he is a simple-minded lover of Kane who needs to put other people down to make himself feel superior. Why are you so obsessed with that guy?

Regarding our second strike with big pharma, I'm not surprised. Again history repeats itself, especially in Kane's case. They've made so many announcements that have amounted to nothing.

Regarding doggie dental water sales increasing, that's fantastic. But I seriously doubt that they will ever cover their cost of sales in the near to mid term. In the long term they definitely will need many more cash infusions, tight fiscal management and a solid and targeted marketing plan to reach any form of sustainability.

Lastly, anyone else suspect that insider information led to the dump of 200,000 shares at .03?

GLTA




Bullboard Posts